Program
berobenatide
Also written as “Berobenatide”, “PF-08653944” and “MET097”.
In Pfizer’s pipeline, GLP-1 receptor agonist
. Its studies are mostly in Obesity · Urinary Incontinence, Stress · Sleep Apnea, Obstructive · Sleep Apnea Syndromes · Diabetes Mellitus, Type 2, led by Pfizer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 2317 open or running | phase 3since Dec 29, 2025 | Nov 27, 2024 | Jan 27, 2027phase 1 · NCT07508241 |
- Named in Pfizer’s own pipeline as
berobenatide PF-08653944
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 27, 2024.
- Mar 13, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT06897202 · 133 enrolled · United States
- Apr 3, 2025Phase 2 study in ObesityNCT06924320 · 201 enrolled · United States
- May 6, 2025Phase 2 study in ObesityNCT06973720 · 268 enrolled · United States
- Jul 10, 2025Named berobenatideINNProposed as its International Nonproprietary Name in WHO's List 133 · before, PF-08653944, MET097
- Dec 29, 2025Phase 3 study in ObesityPhase 3 reachedNCT07311850 · 3,578 enrolled · United States, Bulgaria, Canada and more
- Feb 3, 2026Phase 1 study in OverweightNCT07400679 · 48 enrolled · United States
- Feb 3, 2026Phase 3 study in ObesityNCT07400653 · 1,078 enrolled · United States, Argentina, Bulgaria and more
- Mar 27, 2026Phase 1 study in ObesityNCT07508241 · 22 enrolled · United States
- Apr 2, 2026Phase 1 study in HealthyNCT07519135 · 26 planned · United States
- May 12, 2026Phase 3 study in ObesityNCT07595549 · 954 planned · United States, Brazil, Canada and more
- Aug 25, 20263 phase 3 studies in ObesityNCT07792954, NCT07794774, NCT07794761
- Sep 11, 20263 phase 3 studiesNCT07823608, NCT07845500, NCT07874633
- Sep 22, 2026Phase 1 study in OverweightNCT07845513 · 11 enrolled · China
- Oct 9, 20264 phase 3 studiesNCT07881757, NCT07919678, NCT07915609 and 1 more
- Oct 9, 2026Phase 1 study in OverweightNCT07876531 · 144 planned · United States
Ahead
- Jan 27, 2027Primary completion: phase 1 study in ObesityNCT07508241
- Feb 21, 2027Primary completion: phase 1 study in OverweightNCT07845513
- Apr 6, 2027Primary completion: phase 1 study in OverweightNCT07876531
- Jul 9, 2027Primary completion: phase 1 study in HealthyNCT07519135
TargetBeta
“GLP-1 receptor agonist”the company's pipeline, read by Claude · source
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07932925Urinary Incontinence, Stress | 3 | Not yet recruiting | Oct 13, 2028 | 900 |
| NCT07919678Obesity · United States, Canada | 3 | Recruiting | Aug 22, 2028 | 656 |
| NCT07915609Obesity · United States | 3 | Recruiting | Aug 21, 2028 | 756 |
| NCT07881757Apnea · United States | 3 | Recruiting | Jun 1, 2028 | 258 |
| NCT07876531Overweight · United States | 1 | Recruiting | Apr 6, 2027 | 144 |
| NCT07874633Obesity · China | 3 | Recruiting | Jun 6, 2028 | 432 |
| NCT07845513Overweight · China | 1 | Active, not recruiting | Feb 21, 2027 | 11 |
| NCT07845500Obesity · United States, Australia | 3 | Recruiting | Feb 16, 2028 | 660 |
| NCT07823608Apnea · United States | 3 | Recruiting | Apr 30, 2028 | 258 |
| NCT07794774Obesity · Japan | 3 | Recruiting | Feb 21, 2029 | 197 |
| NCT07794761Obesity · Japan | 3 | Recruiting | Mar 14, 2029 | 180 |
| NCT07792954Obesity · China | 3 | Recruiting | Mar 14, 2028 | 300 |
| NCT07595549Obesity · United States, Brazil, Canada and more | 3 | Recruiting | May 4, 2028 | 954 |
| NCT07519135Healthy · United States | 1 | Recruiting | Jul 9, 2027 | 26 |
| NCT07508241Obesity · United States | 1 | Active, not recruiting | Jan 27, 2027 | 22 |
| NCT07400679Overweight · United States | 1 | Completed | Jul 2, 2026 | 48 |
| NCT07400653Obesity · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | Oct 12, 2027 | 1,078 |
| NCT07311850Obesity · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | Sep 21, 2027 | 3,578 |
| NCT06973720Obesity · United States | 2 | Completed | Dec 16, 2025 | 268 |
| NCT06924320Obesity · United States | 2 | Completed | Sep 29, 2026 | 201 |
| NCT06897202Diabetes Mellitus, Type 2 · United States | 2 | Completed | Dec 29, 2025 | 133 |
| NCT06857617Obesity · United States | 2 | Completed | Jan 3, 2025 | 120 |
| NCT06712836Obesity · United States | 2 | Completed | Jul 3, 2025 | 239 |
How it is read
Names in the registry
- “Berobenatide”, 11 entries
- “PF-08653944”, 6 entries
- “MET097”, 4 entries
- “MET097 Injection”, 1 entry
- “(Part C) MET097”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 18 studies
- Urinary Incontinence, Stress, 1 study
- Sleep Apnea, Obstructive, 1 study
- Sleep Apnea Syndromes, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.